Skip to main content
Delfa

← All assets

Verubecestat

5 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

5

Ongoing

0

Recruiting

0

Completed

3

Sites

0

Countries

0

Endpoints

84

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 84 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
3
Phase 2/3
1
Phase 3
1

Trials by status

Completed
3
Terminated
2

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Safety / tolerability / PK
29
Global cognition
20
Other (unclassified)
12
Function / daily living
6
Amyloid biomarkers
6
Tau biomarkers
4
Neuroimaging
4
Behavior / neuropsychiatric
2
Fluid / digital biomarkers
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 26 of 84 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

10

ADCS-Activities of Daily Living (ADCS-ADL)Function

6

ADAS-CogCognition

6

Neuropsychiatric Inventory (NPI)Behavior

2

Mini-Mental State Examination (MMSE)Cognition

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

5 of 5

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
APECSEfficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)

Verubecestat

Alzheimer’s disease, MCI / preclinical Alzheimer’s

prodromal ADPh 3Terminated0Apr 20185results
EPOCHAn Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)

Verubecestat

Alzheimer’s disease

Alzheimer's diseasePh 2/3Terminated0Apr 20177results
NCT01496170A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])

Verubecestat

Alzheimer’s disease

mild-to-moderate ADPh 1Completed0Jun 20121
NCT01537757A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])

Verubecestat

Alzheimer’s disease

Healthy volunteersPh 1Completed0May 2012-
NCT02910739An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)

Verubecestat

Alzheimer’s disease, MCI / preclinical Alzheimer’s

Age 45-85Ph 1Completed0Apr 2017-results

Showing 1-5 of 5 trials